Aligning with Toshiba, Abbott Nearly Completes its Diagnostics Line
A market leader in most diagnostic technology categories, immunoassay, hematology, and blood glucose, Abbott has historically stumbled in clinical chemistry. But with customers wanting broader options from fewer suppliers, Abbott knew it had to make its move in chemistry. Earlier in 1997, it bought Alcyon Analyzer, a small French company. But with this deal with Toshiba, Abbott is poised to make a major move.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.